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with increased CD86 and MHC II expression and enhanced 
proinflammatory IL-1β cytokine secretion. Finally, increased 
CD86 and MHC II expression was detected in  H. pylori -infect-
ed STAT3 knockout DCs when compared to WT controls. To-
gether, these results demonstrate that  H. pylori infection in-
duces IL-10 secretion in DCs, which activates STAT3, thereby 
modulating DC maturation and reducing IL-1β secretion. 
These findings identify a host molecular mechanism by 
which  H. pylori can manipulate the innate immune response 
to potentially favor chronic infection and promote carcino-
genesis.  © 2014 S. Karger AG, Basel 
 Introduction 
 Helicobacter pylori infects almost 50% of the world-
wide human population and is a significant risk factor for 
the development of gastric cancer  [1, 2] .  H. pylori infec-
tion induces an inflammatory response in the gastric mu-
cosa consisting of infiltrating lymphocytes, neutrophils 
and dendritic cells (DCs) that is insufficient to eradicate 
infection, indicating that the bacterium has developed 
mechanisms to subvert the host immune response. DCs 
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 Abstract 
 Helicobacter pylori infects the human gastric mucosa causing 
a chronic infection that is the primary risk factor for gastric 
cancer development. Recent studies demonstrate that  H. py-
lori promotes tolerogenic dendritic cell (DC) development 
indicating that this bacterium evades the host immune re-
sponse. However, the signaling pathways involved in modu-
lating DC activation during infection remain unclear. Here, 
we report that H. pylori infection activated the signal trans-
ducer and activator of transcription 3 (STAT3) pathway in 
murine bone marrow-derived DCs (BMDCs) and splenic DCs 
isolated ex vivo. Isogenic  cagA- ,  cagE- ,  vacA- and urease-mu-
tants exhibited levels of phosphoSTAT3 that were compa-
rable to in the wild-type (WT) parent strain.  H. pylori -infected 
BMDCs produced increased immunosuppressive IL-10, 
which activated STAT3 in an autocrine/paracrine fashion. 
Neutralization of IL-10 prevented  H. pylori -mediated  STAT3 
activation in both BMDCs and splenic DCs. In addition, anti-
IL-10 treatment of infected  H. pylori -BMDCs was associated 
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are key modulators of the host adaptive immune response 
 [3] . Upon encounters with antigens, immature DCs take 
up, process and present antigenic fragments on surface 
MHC II molecules and display elevated levels of the mat-
uration markers CD80/86 and MHC II. Mature DCs se-
crete specific cytokines to drive the differentiation of the 
T cell into distinct helper T (Th) cell subsets, including 
Th1, Th2 and Th17, each of which responds to specific 
pathogens or antigens. In addition, DCs can drive the de-
velopment of regulatory T cells (Tregs) to prevent im-
mune reactivity to autoantigens and commensal bacteria, 
thereby promoting immunologic tolerance. Tolerogenic 
DCs can promote immune tolerance by deleting autore-
active T cells, priming anergic T cells or promoting Treg 
development  [3] . Treg-inducing DCs express reduced 
levels of maturation molecules such as MHC II, CD80 
and CD86, and secrete high levels of the immunosuppres-
sive cytokine IL-10 compared to classically activated DCs 
 [3] . Importantly, the presence of IL-10 during maturation 
drives the production of tolerogenic DCs, creating a pos-
itive feedback loop to induce maturation of more tolero-
genic DCs. 
 Several recent studies indicate that  H. pylori infection 
promotes the development of tolerogenic DCs, both in 
vitro in a coculture system and in vivo in murine models 
 [4, 5] .  H. pylori infection of neonatal mice induces the de-
velopment of DCs that preferentially induce Tregs in co-
culture. DC depletion prior to infection in neonatal mice 
promotes more severe gastritis and reduces bacterial col-
onization, providing support for the role of these tolero-
genic DCs in modulating infection. In another study, the 
adoptive transfer of  H. pylori -stimulated DCs into mice 
prior to orogastric infection promoted the development 
of increased  H. pylori -specific Tregs  [4] . In murine mod-
els of inflammatory disease, the reprogramming of DCs 
by  H. pylori infection or exposure to  H. pylori DNA is 
protective against allergic asthma and colitis, respectively 
 [5, 6] . In addition, impaired DC function may contribute 
to carcinogenesis during chronic infection. Taken togeth-
er, these studies indicate that  H. pylori promotes the de-
velopment of tolerogenic DCs. However, the exact host 
cell signaling mechanisms by which  H. pylori  modulates 
DC activity remain unclear. 
 Signal transducer and activator of transcription 
(STAT)3 is a member of the STAT family of signal trans-
ducer proteins that are activated by tyrosine phosphory-
lation cascades in response to ligand binding. STAT3 is 
activated in response to cytokines and growth factors 
such as IL-6, IL-10 and vascular endothelial growth factor 
 [7] . Ligand binding to its cognate cell surface receptor 
promotes dimerization with the gp130 subunit, resulting 
in the phosphorylation and activation of associated Janus 
kinase (JAK) 2 enzymes that subsequently recruit cyto-
plasmic STAT3 to the gp130 subunit  [8] . STAT3 becomes 
phosphorylated on Y705, and dimerizes through Src-ho-
mology 2 domain (SH2) phosphotyrosine interactions. 
Phosphorylated STAT3 then translocates into the nucle-
us  [9] , where it binds to promoter regions of target genes 
involved in cell maturation, growth, proliferation, angio-
genesis and immune function  [8, 10, 11] . 
 In DCs, STAT3 activation inhibits DC activation and 
chemical or genetic inhibition of STAT3 activity pro-
motes DC maturation  [7, 12] . IL-10 signals via the STAT3 
pathway, and the presence of this cytokine during DC 
maturation produces tolerogenic DCs  [3] . In this study, 
we determined whether  H. pylori activates STAT3 in DCs 
as a potential means of subverting the host immune re-
sponse to promote chronic infection.
 Materials and Methods 
 Bone Marrow-Derived DCs 
 Bone marrow-derived DCs (BMDCs) were obtained and cul-
tured from C57BL6 wild-type (WT) mice that were 6–8 weeks of 
age. DCs were also obtained from STAT3 CD11c-Cre knockout 
(KO) mice or littermate controls  [12] . Animal treatment and care 
was carried out according to the guidelines outlined by the Sick-
Kids Lab Animal Services. Bone marrow was extracted from the 
femur and tibia and seeded at 2 × 10 5 cells/ml with DC media  [13] . 
DC media contains: RPMI-1640 media, 10% fetal bovine serum, 
1%  L -glutamine, 1% penicillin/streptomycin, 1X sodium pyruvate, 
1X nonessential amino acids and 0.1% 2-mercaptoethanol. Re-
combinant murine GM-CSF was added at a concentration of 40 
ng/ml for stimulating DC growth  [13] . DCs were seeded on bacte-
riological Petri dishes with 10 ml DC media supplemented with 
GM-CSF for 3 days at 37  °  C in 5% CO 2 . On day 3, an additional 10 
ml of DC media supplemented with GM-CSF was added to each 
plate. On day 6 and day 8, 10 ml of the solution from each plate 
was removed, centrifuged to pellet floating cells, and resuspended 
with 10 ml of fresh DC media supplemented with GM-CSF per 
plate. On day 10, the floating, nonadherent cell population (i.e. im-
mature DCs) was harvested, counted and plated in 6-well tissue 
culture plates in antibiotic-free DC media to be used for treatment/
infection.
 Isolation of Splenic DCs for in vitro Culture 
 Splenic DCs were obtained from the spleens of B16-Flt3L-treat-
ed C57BL/6 mice. Briefly, the mice were inoculated with 0.5–1 × 10 6 
B16 melanoma cells overexpressing Flt3L for 12–14 days. Spleens 
were isolated, minced and digested with collagenase and DNase-I 
for 0.5 h at 37  °  C, and incubated in PBS containing 2 m M EDTA and 
5% FCS for 10 min at room temperature. Mononuclear cells were 
isolated by Nycodenz density gradient centrifugation. Negative se-
lection for lineage markers and Gr-1 was performed using biotin-
conjugated antibodies (Becton Dickson, San Jose, Calif., USA) and 
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streptavidin-immunomagenetic beads (Miltenyi). Cells were fur-
ther enriched for CD11c + cells by positive selection using CD11c + -
immunomagnetic beads (Miltenyi). The purity of the cell popula-
tion used was routinely 95% based on reanalyzed samples.
 Treatment/Infection of DCs 
 H. pylori strain 60190 (ATCC 43526  cagA+ , cagE+ ,  vacA 
s1m1+ ) and its isogenic  cagA- ,  cagE- ,  vacA- and urease-mutants 
and the gerbil-adapted carcinogenic strain 7.13 ( cagA+ , cagE+ and 
vacA -)  and its corresponding isogenic  cagA- mutant were cultured 
as described previously on Columbia blood agar plates (supple-
mented with 5% sheep blood) under microaerophilic conditions 
(5% O 2 , 10% CO 2 and 85% N 2 ) for 72 h  [14, 15] . Bacteria were col-
lected using sterile inoculation loops and transferred into a bacte-
rial flask containing Brucella broth supplemented with 10% fetal 
bovine serum for 24 h. Bacteria were then harvested by centrifuga-
tion, resuspended in DC media and added to immature DCs at a 
multiplicity of infection (MOI) of 25: 1, 10: 1, 5: 1, or 1: 1. Treated 
cells were incubated at 37   °   C for 20 h. Untreated DCs served as 
control cells. DCs treated with IL-6 (100 ng/ml) served as a positive 
control for STAT3 activation  [16] . The concentration of IL-6 em-
ployed was based on previous studies assessing STAT3 activation 
in epithelial cells  [15] . Groups of DCs were treated with low-dose 
 Escherichia coli lipopolysaccharide (LPS; Sigma Aldrich) at a min-
imal concentration (1 ng/ml) determined to induce DC matura-
tion  [17] . In some experiments, DCs were treated with a neutral-
izing rat-anti-mouse IL-10 antibody (0.5 μg/ml or 1 μg/ml; eBio-
science, San Diego, Calif., USA) or a rat-anti-IgG antibody (1 μg/
ml; BioLegend, San Diego, Calif., USA). After 20 h of incubation, 
the cells were harvested for analysis. 
 Western Blotting 
 After 20 h of treatment/infection, cells were harvested by vig-
orous pipetting and washed with phosphate-buffered saline 
(PBS; Sigma Aldrich). Cells were lysed using 100 μl of a radioim-
munoprecipitation assay buffer cocktail supplemented with pro-
tease inhibitors on ice. Lysates were centrifuged, and superna-
tants were collected and stored at –20   °   C  [15] . Lysates (supple-
mented with 10% Laemelli buffer) were loaded onto 12% 
SDS-polyacrylamide gels and run at 110 V at room temperature 
for 1.5 h. Separated proteins were transferred onto nitrocellulose 
membrane (BioTrance, NT; Pall Corp., Ann Arbor, Mich., USA) 
at 30 V for 8 h at 4   °   C  [15] . Membranes were then blocked with 
5% skim milk made using Tris-buffered saline supplemented 
with tween (TBST) for 30 min, followed by overnight incubation 
at 4   °   C using rabbit-anti-phosphorylated STAT3 (PSTAT3) anti-
body (1: 200; Cell Signaling, Mass., USA) and mouse-anti-actin 
antibody (1: 10,000) in TBST milk. Blots were then incubated us-
ing corresponding horseradish peroxidase-conjugated second-
ary antibodies (1: 2,000 and 1: 10,000 for the PSTAT3 and actin 
primary antibodies, respectively) for 1 h at room temperature 
 [15] . Bands were then visualized by chemiluminescence using 
Kodak Biomax MR film or FluorChem E Imager (Proteinsimple, 
Santa Clara, Calif., USA). 
 Densitometric Analysis 
 Densitometry was performed utilizing the FlourChem FCII 
software. Densities of PSTAT3 and actin bands were measured for 
each treatment and expressed as a ratio of PSTAT3/actin, normal-
ized to the control treatment.
 Flow Cytometry 
 After 20 h of treatment/infection, DCs were harvested by vigor-
ous pipetting and centrifuged at 350  g for 10 min. Supernatants 
were collected and stored at –80   °   C to examine cytokine release 
profile. Cells were rinsed using flow cytometry buffer (PBS supple-
mented with 1% BSA), and then incubated with 25 μg/μl anti-
CD16/32 (FC receptor block; eBioscience) for 15 min on ice, to 
block nonspecific antibody binding  [18] . BMDCs were then incu-
bated with FITC-labeled αCD11c, PE-labeled αCD86 and APC-la-
beled αMHC class II antibodies (all from eBioscience) for 30 min. 
Isolated splenic DCs were incubated with FITC-labeled αCD11c, 
PE-labeled αCD86 and PE-Cy7-labeled αMHC class II antibodies 
and subsequently incubated with 7-AAD viability staining solution 
(eBioscience). DCs were then washed twice with FBS before fixa-
tion using 1% paraformaldehyde (made with PBS) for 20 min. Cells 
were subsequently washed with flow cytometry buffer and analyzed 
using a LSR-II flow cytometer (Becton Dickson). Flow cytometry 
data was then analyzed utilizing FlowJo software (Tree Star Inc., 
Ashland, Oreg., USA). Live BMDCS were selected based on the size, 
complexity and expression of the DC-specific marker CD11c. Pop-
ulations were analyzed based on the proportion of cells positive for 
the maturation markers MHC II and CD86 (mature DCs). Live 
isolated splenic DCs were selected based on exclusion of the 7-AAD 
viability staining solution, size and complexity, and the expression 
of the DC-specific marker CD11c. 
 Multiplex Bead-Based Luminex Assay 
 DCs were infected for 20 h as described above. Supernatants 
were collected and stored at –80  °  C. Supernatants from DCs were 
assayed for the CD40 ligand, GM-CSF, IFN-γ, IL-10, IL-12 (p70), 
IL-13, IL-15, IL-17A, IL-17E/IL-25, IL-17F, IL-1β, IL-2, IL-21, IL-
22, IL-23, IL-27, IL-28B, IL-31, IL-33, IL-4, IL-5, IL-6, MIP-3α/
CCL20, TNFα and TNFβ, using the mouse Th17 magnetic bead 
kit (EMD Millipore, Billerica, Mass., USA). The service was per-
formed by the Centre for the Study of Complex Childhood Dis-
eases at the Hospital for Sick Children, Toronto, Ont., Canada.
 ELISA Assay 
 Isolated splenic DCs were infected for 20 h as described above. 
Supernatants were collected and stored at –80   °   C. Supernatants 
from DCs were assayed for IL-1β and IL-10 using the mouse quan-
tikine IL-1β and IL-10 kits, respectively (R&D Systems).
 STAT3 KO Mice 
 STAT3 KO mice were kindly donated by the laboratories of Dr. 
Tak Mak and Dr. Christian Schindler. These DC-specific STAT3 
KO mice were generated using a Cre-flox system as described pre-
viously  [12] . Briefly, STAT3 flox/flox mice in a 129/C57BL/6J mixed 
background were crossed seven generations onto C57BL/6J back-
ground, and then with CD11c-BAC-Cre transgenic mice. STAT3 
expression was assessed in cell lysates via immunoblotting to con-
firm knockout.
 Statistical Analysis 
 All experiments were performed at least 3 times, and statistical 
significance was calculated using the Kruskal-Wallis nonparamet-
ric 1-way analysis of variance (ANOVA) testing to compare the 
means ± SE for independent treatment groups followed by Dunn’s 
testing or a 1-way ANOVA to compare the means ± SE where 
noted. A p value <0.05 was considered statistically significant.
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 Results 
 H. pylori Infection Activates STAT3 in DCs 
 To determine whether  H. pylori  infection  induces ac-
tivation of the STAT3 pathway in DCs, expression of 
PSTAT3 was measured in BMDC lysates following infec-
tion with the carcinogenic  H. pylori strain 7.13 at a MOI 
of 10: 1. Similar to cells treated with the known STAT3 
activator IL-6, DCs incubated with  H. pylori showed in-
creased phosphorylation of STAT3 in comparison with 
uninfected control and LPS-treated DCs ( fig. 1 a). Consis-
tent with the findings in BMDCs, an increase in STAT3 
phosphorylation was detected in isolated murine splenic-
derived DCs indicating that this finding was not unique 
to BMDCs ( fig. 1 b). Next, we determined if specific bacte-
rial virulence factors were responsible for the phosphory-
lation of STAT3. Expression of PSTAT3 was measured in 
BMDC lysates following infection with either  H. pylori 
strain 7.13 or strain 60190, and corresponding isogenic 
 cagA- ,  cagE- , vacA- and urease-mutant strains.  H. pylori 
strain 7.13  cagA- as well as strain 60190 isogenic  cagA- , 
cagE- , vacA- and urease-mutants increased PSTAT3 ex-
pression in DC lysates that was comparable to the corre-
sponding parental WT strains ( fig. 1 c). 
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 Fig. 1.  H. pylori activates the STAT3 pathway in DCs.  a Lysates 
from BMDCs incubated with  H. pylori strain 7.13 at a MOI of 10: 
 1, IL-6 (100 ng/ml) or  E. coli LPS (1 ng/ml) for 20 h were subjected 
to immunoblot analysis to examine changes in STAT3 phosphory-
lation. The graph represents the densitometric analysis of PSTAT3 
bands normalized to actin bands, normalized to control-treated 
cells.  *   p < 0.05;  * * *  p < 0.001 using the Kruskal-Wallis test (n = 5). 
 b Lysates from splenic-derived DCs incubated with  H. pylori strain 
7.13 at a MOI of 10: 1 or IL-6 (100 ng/ml) for 20 h were subjected 
to immunoblot analysis to determine changes in STAT3 phos-
phorylation.  c Lysates from BMDCs incubated with  H. pylori 
strain 7.13, its isogenic  cagA- mutant or  H. pylori strain 60190 and 
its isogenic  cagA-, cagE-, vacA- and urease-mutants, at a MOI of 
10: 1 for 20 h were subjected to immunoblot analysis to determine 
changes in STAT3 phosphorylation. The graph represents the den-
sitometric analysis of PSTAT3 bands normalized to actin bands, 
normalized to control-treated cells.  a–c C = Control; HP =  H. py-
lori strain.  a ,  c Columns: means, bars: SEM.
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 H. pylori Infection Upregulates Expression of DC 
Maturation Markers 
 We next assessed the effect of  H. pylori infection on 
DC maturation. BMDCs were treated with IL-6 (100 ng/
ml),  E. coli  LPS (1 ng/ml) or  H. pylori  strain 7.13 at a MOI 
of 10: 1 and incubated for 20 h. Untreated cells served as 
controls. DCs from each treatment condition were stained 
with αCD11c, αCD86 and αMHC class II fluorophores, 
and flow cytometry analysis was performed to quantify 
expression of the maturation markers. Live cells express-
ing the DC marker CD11c were selected for analysis 
( fig. 2 a). In comparison with LPS-treated cells, two dis-
tinct populations of CD11c + cells were detected following 
infection, the MHC II low CD86 low population represent-
ing immature DCs and the MHC II hi CD86 hi representing 
mature DCs ( fig.  2 b).  H. pylori infection increased the 
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 Fig. 2.  H. pylori infection induces expression of DC maturation 
markers.  a Live BMDCs were selected based on their size (for-
ward-scatter characteristic, FSC), complexity (side-scatter char-
acteristic, SSC) and expression of the DC-specific marker CD11c. 
 b   BMDCs were incubated with  H. pylori strain 7.13 at a MOI of 
10: 1, IL-6 (100 ng/ml) or  E. coli LPS (1 ng/ml) for 20 h. Flow cy-
tometry analysis was used to quantify the population expressing 
high levels of the maturation markers CD86 and MHC class II. 
Cells in the gated population in the upper right quadrant of each 
graph represent the DCs with a high expression of both markers 
(i.e. mature DCs). Quadrants were set using FMO staining con-
trols. Data are from 1 representative experiment.  c Quantification 
of gated CD86 hi MHC II hi DCs.  *   p < 0.05 using a Kruskal-Wallis 
test (n = 6).  
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proportion of MHC II hi CD86 hi CD11c + DCs to an extent 
similar to DCs treated with low-concentration  E. coli LPS. 
In cells treated with IL-6, the expression of these matura-
tion markers was comparable to untreated (control) cells 
( fig. 2 b, c).
 Next, we assessed the expression of maturation mark-
ers in isolated splenic DCs. Isolated splenic DCs displayed 
a high level of spontaneous maturation. Similar to  BMDCs, 
 H. pylori infection (MOI 1: 1) increased the proportion 
of MHC II hi CD86 hi CD11c + DCs (online suppl. fig. S1; 
for  all online suppl. material, see www.karger.com/
doi/10.1159/000368232). However, when the multiplicity 
of infection increased to 5: 1 and 10: 1, the degree of matu-
ration was comparable to the untreated controls. We next 
measured expression of the maturation marker CD86, as 
assessed by the mean fluorescence intensity (MFI) of 
CD86 ( fig. 2 d).  H. pylori infection at the low MOI of 1: 1 
increased the MFI of CD86. Interestingly, increasing the 
MOI of  H. pylori ameliorated the increased CD86 expres-
sion in splenic DCs in a dose-dependent manner ( fig. 2 d). 
Taken together, these findings suggest that  H. pylori is able 
to inhibit DC maturation at an increased MOI.  H. pylori 
infection did not alter the MFI of MHC II in isolated 
splenic DCs in comparison with controls.
 STAT3 Inhibits DC Maturation During H. pylori 
Infection 
 Previous studies suggest that STAT3 activation is a 
negative regulator of DC function and maturation  [12] . 
To characterize the effect of  H. pylori -induced STAT3 ac-
tivation on DC maturation, we utilized BMDCs obtained 
from mice in which the STAT3 gene was targeted for de-
letion in DCs using a CD11c-Cre transgene as described 
previously  [12] . DC-specific Cre + STAT3 KO and litter-
mate Cre – (WT) DCs were treated with IL-6 (100 ng/ml), 
 E. coli  LPS (1 ng/ml) or  H. pylori  strains 7.13 or 60190. 
Sets of STAT3 KO and WT DCs were then lysed and im-
munoblotted to determine STAT3 expression and activa-
tion. In comparison with DCs from control littermates, 
STAT3 KO (Cre + ) DCs lacked STAT3 phosphorylation in 
response to either  H. pylori infection or IL-6 treatment, 
confirming the absence of STAT3 ( fig.  3 a). In parallel, 
flow cytometry was performed to assess the expression of 
the DC maturation markers CD86 and MHC class II. 
 H.  pylori -infected STAT3 KO DCs  displayed enhanced 
maturation as assessed by expression of maturation 
markers using flow cytometry ( fig. 3 b, c). Taken together, 
these studies suggest that STAT3 activation in DCs blunts 
maturation.
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 Fig. 2.  H. pylori infection induces expression of DC maturation 
markers.  d Splenic DCs were incubated with  H. pylori strain 7.13 
(MOI 10: 1, 5: 1 or 1: 1), IL-6 (100 ng/ml) or  E. coli LPS (1 μg/ml) 
for 20 h. Flow cytometry analysis was used to quantify the popula-
tion expressing high levels of the maturation markers CD86 and 
MHC class II in live splenic DCs. Live splenic DCs were selected 
based on exclusion of the 7-AAD viability staining solution, size 
and complexity (FSC and SSC, respectively), and expression of the 
DC-specific marker CD11c (gating strategy shown in online suppl. 
fig. S1). The MFI of CD86 and MHC II expression was quantified 
in this population of cells.  *  p < 0.05 using the Kruskal-Wallis test 
(n = 3).  b–d C = Control; HP =  H. pylori strain.  c ,  d Columns: 
means, bars: SEM. 
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 Activated DCs Secrete Immunosuppressive IL-10 in 
Response to H. pylori Infection 
 As the cytokines released from DCs instruct the T cell 
phenotype that develops, and thus dictate the adaptive 
immune response, we examined the cytokine release pro-
file from  H. pylori -infected DCs.  H. pylori treatment sig-
nificantly increased the levels of the anti-inflammatory 
cytokine IL-10 in the BMDC culture supernatants com-
pared to control, IL-6-, and LPS-treated cell supernatants 
( fig. 4 a). The levels of the proinflammatory cytokine IL-
1β were also increased in  H. pylori -infected BMDCs com-
pared to controls and LPS-treated cells ( fig. 4 a). Further-
more, both  H. pylori and  E. coli  LPS induced comparable 
levels of increased secretion of IL-6, IL-25, IL-13, IL-17A, 
TNFα and IL-23 in the DC culture supernatants in com-
parison with the controls or IL-6-treated DC superna-
tants ( fig. 4 b). Similar to BMDCs,  H. pylori  infection sig-
nificantly increased levels of IL-10 and IL-1β in isolated 
splenic DC culture supernatants compared to in the con-
trols ( fig. 4 c).
 H. pylori-Mediated IL-10 Secretion Induces STAT3 
Activation in DCs and Inhibits Maturation  
 Cytokines including IL-6 or IL-10 activate the STAT3 
pathway. As a marked increase in IL-10 secretion was 
identified in  H. pylori -infected DC supernatants in com-
parison with the controls or the LPS-treated cells, we next 
determined whether the increased IL-10 secretion was re-
sponsible for STAT3 phosphorylation. To investigate the 
functional effects of DC IL-10 secretion, DCs were incu-
bated with a neutralizing α-IL-10 antibody (1 μg/ml) in 
the presence or absence of  H. pylori . DCs were lysed and 
immunoblotting was performed to examine the phos-
phorylation of STAT3. Treatment with the α-IL-10 anti-
body abrogated the STAT3 phosphorylation induced by 
 H. pylori  in the DCs ( fig. 5 a). Similarly, α-IL-10 treatment 
prevented STAT3 phosphorylation in isolated splenic 
DCs treated with  H. pylori ( fig. 5 b). Incubation with an 
isotype IgG antibody (1 μg/ml) had no effect on  H. pylori -
mediated STAT3 phosphorylation.
 Previous studies implicate IL-10-mediated STAT3 ac-
tivation in the inhibition of DC maturation  [19] . There-
fore we assessed the effect of IL-10 neutralization on the 
expression of DC maturation markers during  H. pylori 
infection. Anti-IL-10 treatment enhanced expression of 
the maturation markers MHC class II and CD86 in DCs 
in response to  H. pylori infection ( fig.  5 c). In contrast, 
treatment with an isotype control antibody had no effect 
on  H. pylori -mediated STAT3 phosphorylation or the ex-
pression of maturation markers (data not shown). 
 H. pylori-Mediated IL-10 Secretion by DCs Reduces 
Secretion of Pro-Inflammatory IL-1β 
 We next determined if the cytokine profile differed in 
α-IL-10-treated  H. pylori -infected cells. Administration 
of the α-IL-10 antibody effectively neutralized the IL-10 
in the  H. pylori -infected  DC culture supernatants ( fig. 6 a). 
Anti-IL-10 treatment of DCs during infection also result-
ed in increased secretion of the cytokine IL-1β, in com-
parison with controls or the isotype antibody-treated cells 
( fig. 6 b). IL-1β is a pleiotropic proinflammatory cytokine 
that is involved in the activation of the immune response 
and the induction of DC maturation  [20] . Taken togeth-
er, these findings indicate that the IL-10 secreted by  H. 
pylori -infected DCs blunts not only DC maturation but 
also the secretion of the proinflammatory mediator IL-
1β. 
 Discussion 
 The ability to alter and evade the host immune re-
sponse is crucial for the survival and persistence of 
 H.  pylori in the host gastric mucosa. As DCs are key or-
chestrators of the host immune response, they are ideal 
targets for the pathogen’s immunity-manipulating ef-
forts. Furthermore, altered DC function could promote 
tumor immune evasion. Current evidence indicates that 
 H. pylori infection prevents DC activation and matura-
tion  [4–6] . However, the mechanism by which  H. pylori 
alters DC function remains unclear. 
 We showed, for the first time, that  H. pylori activated 
the STAT3 pathway in murine BMDCs and isolated 
splenic DCs. Furthermore, we determined that  H. pylo-
ri -mediated IL-10 release was responsible for the activa-
tion of STAT3. IL-10 is a multifunctional immunoregu-
latory cytokine that acts as an inhibitor of DC matura-
tion and function, and also drives the production of 
tolerogenic DCs  [3, 21] . IL-10 also activates the STAT3 
pathway  [7] . In comparison to DCs treated with  E. coli 
 LPS,  H. pylori -stimulated DCs secreted increased levels 
of IL-10 and IL-1β in both BMDCs and isolated splenic 
DCs. These findings are consistent with previous studies 
that identified increased IL-10 secretion in  H. pylori -
stimulated DCs  [4, 5] . Employing an IL-10-neutralizing 
antibody, we confirmed that  H. pylori -mediated IL-10 
secretion was sufficient to activate STAT3 in DCs. Thus, 
although some studies indicate that IL-1β may also acti-
vate STAT3 in other cell types, our findings indicate that 
IL-10 is the key cytokine responsible for STAT3 activa-
tion in  H. pylori -treated DCs. As both IL-6 and IL-10 
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 Fig. 4.  H. pylori induces secretion of IL-10 from DCs.  a The mouse 
Th17 magnetic bead panel assay was used to assess cytokine secre-
tion in cell supernatants obtained from BMDCs incubated with 
either  E. coli  LPS (1 ng/ml), IL-6 (100 ng/ml) or WT  H. pylori  strain 
7.13 (MOI 10: 1) for 20 h.  *  p < 0.05;  * *  p < 0.01;  * * *  p < 0.001 using 
1-way ANOVA (n = 4).  b Increases in IL-6, IL-25, IL-13, IL-17A, 
TNFα and IL-23 in response to  H. pylori  infection in comparison 
with treatment with the control and LPS (n = 4).  *  p < 0.05;  * *  p < 
0.01;  * * *  p < 0.001; n.s. p > 0.05 .  c Mouse quantikine IL-1β and IL-
10 ELISA kits were used to assess IL-1β and IL-10 secretion in cell 
supernatants obtained from control and  H. pylori strain 7.13-in-
fected (MOI 10: 1, 5: 1 and 1: 1 for 20 h) splenic DCs.  *  p < 0.05; 
 * *  p < 0.01;  * * *  p < 0.001 using a 1-way ANOVA (n = 3).  a–c C = 
Control; HP =  H. pylori strain. Columns: means, bars: SEM.
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activate STAT3 and are secreted by  H. pylori -infected 
DCs, this raises the question of why IL-10 has such a po-
tent effect on STAT3 activation. In a previous study, 
 IL-10 promoted sustained STAT3 activation in DCs 
in  comparison with IL-6  [22] ; IL-6-mediated tran-
sient STAT3 activation induced a proinflammatory re-
sponse in DCs while IL-10-mediated STAT3 activation 
 promoted an anti-inflammatory response. In our study, 
anti-IL-10 treatment increased DC expression of MHC 
II and CD86 in response to  H. pylori infection, indicat-
ing that this IL-10 autocrine/paracrine activation of 
STAT3 is responsible for the blunted expression of DC 
maturation markers. Interestingly, neutralization of IL-
10 also enhanced the secretion of proinflammatory IL-
1β from  H. pylori -infected DCs, demonstrating that this 
IL-10-mediated STAT3 activation plays an immunoreg-
ulatory role. IL-1β enhances the proliferation and dif-
ferentiation of effector T cells including Th17, Th1 and 
Th2 cells  [23] . IL-1β induces the secretion of cytokines 
such as IL-12 from DCs  [24] , and breaks peripheral tol-
erance by inducing resistance to the suppressive func-
tions of FoxP3+ Tregs  [25] . Neutralization of IL-1β was 
found to reduce IL-17A secretion in CD4 + T cells ob-
tained from subjects previously infected with  H. pylori 
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 Fig. 5. α-IL-10 antibody inhibits  H. pylori -induced STAT3 phos-
phorylation in DCs to promote enhanced expression of matura-
tion markers.  a Lysates from BMDCs treated with functional grade 
α-IL-10 antibody (0.5 or 1 μg/ml) or isotype control IgG antibody 
(1 μg/ml) in the presence or absence of  H. pylori , were subjected to 
immunoblotting analysis to determine STAT3 phosphorylation 
levels. Densitometric analysis was used to quantify the changes in 
STAT3 phosphorylation levels.  *   p < 0.05 using the Kruskal-Wallis 
test (n = 4).  b Lysates from splenic-derived DCs treated with func-
tional grade α-IL-10 antibody (1 μg/ml) or isotype control IgG 
antibody (1 μg/ml) in the presence or absence of  H. pylori were 
subjected to immunoblotting analysis to determine STAT3 phos-
phorylation levels. Data show a representative blot.  c DCs were 
treated with functional grade α-IL-10 antibody (1 μg/ml) or iso-
type control IgG antibody (1 μg/ml) in the presence or absence of 
 H. pylori at a MOI of 10: 1 for 20 h. Flow cytometry analysis was 
used to quantify the population expressing high levels of the matu-
ration markers CD86 and MHC class II. The graph represents 
quantification of the gated CD86 hi MHC II hi DCs (i.e. mature 
DCs).  *   p < 0.05 using the Kruskal-Wallis test (n = 5).  a–c C = Con-
trol; HP =  H. pylori strain.  a ,  c Columns: means, bars: SEM. 
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cocultured with autologous  H. pylori- pulsed antigen-
presenting cells  [26] . Secretion of this proinflammatory 
cytokine by DCs may contribute to the chronic gastritis 
characteristic of  H. pylori infection. 
 In order to specifically address the role of STAT3 acti-
vation in the prevention of DC maturation during  H. py-
lori infection, we employed a genetic deletion model of 
STAT3.  H. pylori infection induced greater expression of 
the maturation markers MHC II and CD86 in STAT3-KO 
DCs when compared to control DCs. Kaebisch et al.  [27] 
 used STATTIC, a chemical inhibitor of STAT3, to attempt 
to block STAT3 activation and characterize the effect on 
 H. pylori -treated human DCs. STATTIC treatment alone 
was not able to block STAT3 activation and did not alter 
DC maturation. However, when STATTIC was used in 
combination with anti-IL-10 treatment, both the inhibi-
tion of STAT3 activation and a corresponding increase in 
DC maturation were identified. Their study supports our 
results, specifically addressing the role of STAT3 in DC 
maturation. The role of STAT3 during  H. pylori infection 
characterized in our study is consistent with the current 
literature that indicates that STAT3 is a negative regulator 
of DC maturation and function  [7, 12, 28] . 
 The exact bacterial factors which promote IL-10 se-
cretion and STAT3 activation in DCs have still to be elu-
cidated. We found that isogenic mutant strains lacking 
either CagA, CagE, VacA or urease were still capable of 
activating STAT3, indicating that these bacterial factors 
were not required for STAT3 activation. Furthermore, 
we found that antibiotic-treated  H. pylori still induced 
STAT3 activation (data not shown), indicating that via-
ble bacteria were not required. In support of our find-
ings, previous studies indicate that the DC sensing of 
bacterial products by Toll-like receptor 2 regulates IL-10 
secretion  [29] . Furthermore, Shiu et al.  [30]  showed that 
Toll-like receptor 2 increased IRAK-M signaling, there-
by contributing to IL-10 secretion during  H. pylori infec-
tion. Alternatively, both γ-glutamyl transpeptidase and 
s2/m2 vacuolating cytotoxin secreted from  H. pylori  have 
been shown to contribute to the development of toleriz-
ing DCs  [31] . More recently, Kaebisch et al.  [27]  showed 
a reduction but not complete inhibition of IL-10 and 
PSTAT3 in human DCs infected with an isogenic  cagA-
 mutant of strain G27 in comparison with the WT strain. 
However, another study found comparable levels of IL-
10 secretion following the infection of human DCs with 
 cag pathogenicity island-positive and negative strains 
 [32] . Similarly, we did not detect a significant reduction 
in PSTAT3 in DCs infected with isogenic  cagA- or  cagE-
 mutants. Methodologic differences may account for the 
apparently conflicting results. Additional studies will be 
required to delineate the exact bacterial factors required 
to activate STAT3.
 Dysregulation of STAT3 is found in many human 
cancers including gastric cancers, and it correlates with 
both tumor progression and poor prognosis  [7] . STAT3 
 Fig. 6. IL-10 inhibits IL-1β secretion from  H. pylori -infected DCs. 
The mouse Th17 magnetic bead panel assay was used to assess IL-
10 ( a ) and IL-1β ( b ) cytokine secretion in cell supernatants ob-
tained from DCs incubated with  H. pylori  for 20 h (MOI 10: 1) in 
the presence or absence of functional grade α-IL-10 antibody 
(1 μg/ml) or a control IgG antibody (1 μg/ml).  *  p < 0.05;  * * *   p < 
0.001; n.s. p > 0.05 using a 1-way ANOVA (n = 4).  a ,  b C = Control; 
HP =  H. pylori strain. Columns: means, bars: SEM.
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activation is detected in  H. pylori -infected gastric tissue 
in humans, and in the gerbil model STAT3 activation is 
associated with carcinogenesis  [15] . Current evidence 
indicates that STAT3 activation in DCs supports a pro-
tumorigenic environment. Many tumors secrete high 
levels of vascular endothelial growth factor, which can 
activate STAT3 in DCs, preventing their maturation 
and thus decreasing host immune tumor surveillance 
 [7] . Furthermore, STAT3-depleted DCs are more resis-
tant to cancer cell-derived inhibitory factors  [28] . These 
STAT3-deficient DCs are more potent activators of T 
cells and have a high capacity to induce Th1 responses 
 [28] . Indeed, several studies have determined that 
 H.  pylori -stimulated DCs promote the development of 
Tregs in vitro  [4–6, 27] and an increase in infiltrating 
Tregs has been detected in murine models of infection 
 [4, 5] as well as in the gastric mucosa of infected humans 
 [33] . Of interest, an increase in Tregs is detected in the 
gastric mucosa of  H. pylori -infected subjects with gas-
tric adenocarcinoma in comparison with  H. pylori -me-
diated chronic gastritis or dysplasia  [34] . Thus STAT3 
activation in DCs during chronic infection with  H. py-
lori may have significant implications for gastric cancer 
development. 
 In conclusion, these results demonstrate that  H. pylori 
infection induces the activation of the STAT3 signaling 
pathway in DCs. As depicted in our proposed model in 
 figure 7 , the IL-10 produced by  H. pylori -stimulated DCs 
may provide a mechanism for altering the balance between 
the levels of proinflammatory and immunoregulatory cy-
tokines. Thus  H. pylori -stimulated DCs may  prevent a 
proper adaptive immune response, thereby favoring 
 H.   pylori persistence and reducing gastric inflammatory 
damage. Importantly, the IL-10 secreted by the DCs acted 
as an autocrine/paracrine activator of STAT3 to blunt DC 
maturation and induce the production of a tolerogenic DC 
phenotype. These tolerogenic DCs may inhibit the devel-
opment of effector T cells, and create a permissive, immu-
noregulatory environment facilitating bacterial persis-
tence. However, this tolerogenic environment may also 
decrease DC tumor immunosurveillance to prevent recog-
nition and DC-mediated immune elimination of develop-
ing tumor cells, contributing to the development of gastric 
cancer as seen in  H. pylori  infection. Overall, this study 
describes a novel mechanism by which  H. pylori alters the 
host immune response to facilitate its persistence, a mech-
anism that may also contribute to the carcinogenic poten-
tial of this pathogen.
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 Fig. 7. Proposed model of DC responses to 
 H. pylori infection.  H. pylori  infection in-
duces immature DCs (iDCs) to secrete IL-
10, which acts in an autocrine and para-
crine fashion to activate STAT3 in DCs, 
thereby blunting DC maturation, reducing 
expression of MHC II and CD86 and secre-
tion of IL-1β from DCs.
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